Cargando…

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer

Estrogen receptor-positive (ER+) breast cancer is the most common form of breast cancer. Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these warranted the development of a new treatment option. CDK4/6 inhibitors address this problem by halting cell cycle prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheidemann, Erin R., Shajahan-Haq, Ayesha N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625090/ https://www.ncbi.nlm.nih.gov/pubmed/34830174 http://dx.doi.org/10.3390/ijms222212292

Ejemplares similares

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
por: Fallah, Yassi, et al.
Publicado: (2021)

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
por: Zhou, Fiona H., et al.
Publicado: (2023)

Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition
por: He, Wei, et al.
Publicado: (2020)

Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
por: Viswanadhapalli, Suryavathi, et al.
Publicado: (2019)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
por: Mo, Hongnan, et al.
Publicado: (2022)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review
por: Militello, Anna Maria, et al.
Publicado: (2019)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
por: O’Sullivan, Ciara C
Publicado: (2015)

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
por: Watt, April C., et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Application of Metabolomics in Drug Resistant Breast Cancer Research
por: Shajahan-Haq, Ayesha N., et al.
Publicado: (2015)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
por: de Melo Gagliato, Debora, et al.
Publicado: (2020)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
por: Viganò, Lucia, et al.
Publicado: (2022)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
por: Matutino, Adriana, et al.
Publicado: (2018)

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer
por: Franks, Jeffrey, et al.
Publicado: (2022)

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
por: Khorrami, Mohammadhadi, et al.
Publicado: (2023)

CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
por: Lee, Jin Sun, et al.
Publicado: (2023)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
por: McDermott, Martina S.J., et al.
Publicado: (2017)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
por: Schedin, Troy B., et al.
Publicado: (2018)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER(+) Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
por: Lawson, Mandy, et al.
Publicado: (2023)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
por: Rodriguez, María Jimena, et al.
Publicado: (2023)

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
por: Pandey, Kamal, et al.
Publicado: (2019)

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
por: Main, Sasha C., et al.
Publicado: (2022)

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer
por: Zhu, Xiang, et al.
Publicado: (2023)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
por: Demas, Diane M., et al.
Publicado: (2019)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jt8os440ire97j9djkg7toqgmv